Kurma Partners and Idinvest Partners have launched Dynacure, a new biotech company based in Strasbourg specializing in treatments for rare neuromuscular disorders. Dynacure is a spin-off based on discoveries made by Dr. Jocelyn Laporte at IGBMC. In its first drug discovery program, Dynacure is partnering with Ionis Pharmaceuticals to develop a new therapeutic using Ionis' antisense technology to target a gene identified by Dr. Laporte's group. Conectus, the technology transfer office for Strasbourg research laboratories, is also involved in Dynacure through its proof-of-concept fund.